BAX Stock Forecast 2025-2026
Distance to BAX Price Targets
BAX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Baxter (BAX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BAX and similar high-potential opportunities.
Latest BAX Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, BAX has a neutral consensus with a median price target of $38.00 (ranging from $30.00 to $55.00). The overall analyst rating is Buy (6.9/10). Currently trading at $30.41, the median forecast implies a 25.0% upside. This outlook is supported by 6 Buy, 11 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Cecilia Furlong at Morgan Stanley, projecting a 80.9% upside. Conversely, the most conservative target is provided by Patrick Wood at Morgan Stanley, suggesting a 1.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BAX Analyst Ratings
BAX Price Target Range
Latest BAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $41.00 |
| Feb 26, 2025 | Goldman Sachs | David Roman | Buy | Reinstates | $42.00 |
| Feb 21, 2025 | JP Morgan | Robbie Marcus | Neutral | Maintains | $36.00 |
| Feb 20, 2025 | Barclays | Matt Miksic | Overweight | Reinstates | $39.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $35.00 |
| Nov 11, 2024 | Stifel | Rick Wise | Buy | Maintains | $38.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $40.00 |
| Aug 8, 2024 | Goldman Sachs | David Roman | Neutral | Maintains | $40.00 |
| Aug 7, 2024 | JP Morgan | Robbie Marcus | Neutral | Maintains | $42.00 |
| Aug 7, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $40.00 |
| Jul 15, 2024 | Morgan Stanley | Patrick Wood | Underweight | Downgrade | $30.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $37.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $45.00 |
| May 30, 2024 | Goldman Sachs | David Roman | Neutral | Initiates | $36.00 |
| May 22, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $38.00 |
| May 10, 2024 | TD Cowen | Joshua Jennings | Hold | Downgrade | $40.00 |
| Apr 3, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $44.00 |
| Mar 5, 2024 | B of A Securities | Travis Steed | Neutral | Maintains | $45.00 |
| Feb 12, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $54.00 |
Baxter International Inc. (BAX) Competitors
The following stocks are similar to Baxter based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Baxter International Inc. (BAX) Financial Data
Baxter International Inc. has a market capitalization of $15.18B with a P/E ratio of 133.8x. The company generates $10.64B in trailing twelve-month revenue with a -6.1% profit margin.
Revenue growth is +1.0% quarter-over-quarter, while maintaining an operating margin of +10.1% and return on equity of -4.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Baxter International Inc. (BAX) Business Model
About Baxter International Inc.
Global healthcare company specializing in medical products.
Baxter International generates revenue by developing and manufacturing a diverse range of medical products, including IV solutions, infusion pumps, and renal therapies. The company serves hospitals and healthcare professionals, focusing on critical care and chronic kidney disease treatments, which are essential in clinical settings.
Founded in 1931 and headquartered in Deerfield, Illinois, Baxter is recognized for its commitment to innovation and quality in healthcare. Its extensive product portfolio positions it as a significant player in the global healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
38,000
CEO
Mr. David Brent Shafer
Country
United States
IPO Year
1981
Website
www.baxter.comBaxter International Inc. (BAX) Latest News & Analysis
Latest News
John Marshall, head of derivatives research at Goldman Sachs, discusses the current market environment and specific companies analyzed by Goldman in a recent 'Money Movers' interview.
Goldman Sachs' insights from derivatives research can indicate market trends and potential investment opportunities, influencing investor sentiment and strategies.
Baxter International Inc. has launched the Hemopatch Sealing Hemostat, now with room temperature storage, enhancing accessibility for surgeons in Europe to control bleeding and prevent leakage.
Baxter's launch of Hemopatch with room temperature storage enhances surgical efficiency and accessibility, potentially driving sales growth and improving market position in Europe.
Baxter International Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 6, 2025, at 9 a.m. CT. In-person attendance is not allowed. Online access starts at 8:45 a.m. CT.
Baxter's shift to a virtual Annual Meeting may enhance accessibility for shareholders, potentially increasing participation and engagement, which can positively impact stock performance and investor sentiment.
CVS Health's stock is the top performer in the S&P 500 this year, despite a poor showing in 2024, and is considered undervalued based on a key valuation metric.
CVS Health's strong performance and its undervalued stock could signal potential for future gains, attracting investors looking for recovery plays in the S&P 500.
BAX introduced its Voalte Linq device with Scotty assistant, a voice-activated technology, at the 2025 HIMSS Global Healthcare Conference.
BAX's launch of the Voalte Linq device showcases innovation in healthcare technology, potentially enhancing market position and attracting investment interest in digital health solutions.
The global medical penlight market, valued at USD 279.7 million in 2024, is projected to grow at a CAGR of 6.6% through 2030, driven by increased demand in eye and ear diagnostics.
The medical penlight market is growing due to rising eye and ear disorders, with a projected CAGR of 6.6%. Advancements in technology and increased preventive healthcare emphasize investment opportunities.
Frequently Asked Questions About BAX Stock
What is Baxter International Inc.'s (BAX) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Baxter International Inc. (BAX) has a median price target of $38.00. The highest price target is $55.00 and the lowest is $30.00.
Is BAX stock a good investment in 2025?
According to current analyst ratings, BAX has 6 Buy ratings, 11 Hold ratings, and 1 Sell ratings. The stock is currently trading at $30.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BAX stock?
Wall Street analysts predict BAX stock could reach $38.00 in the next 12 months. This represents a 25.0% increase from the current price of $30.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Baxter International Inc.'s business model?
Baxter International generates revenue by developing and manufacturing a diverse range of medical products, including IV solutions, infusion pumps, and renal therapies. The company serves hospitals and healthcare professionals, focusing on critical care and chronic kidney disease treatments, which are essential in clinical settings.
What is the highest forecasted price for BAX Baxter International Inc.?
The highest price target for BAX is $55.00 from Cecilia Furlong at Morgan Stanley, which represents a 80.9% increase from the current price of $30.41.
What is the lowest forecasted price for BAX Baxter International Inc.?
The lowest price target for BAX is $30.00 from Patrick Wood at Morgan Stanley, which represents a -1.3% decrease from the current price of $30.41.
What is the overall BAX consensus from analysts for Baxter International Inc.?
The overall analyst consensus for BAX is neutral. Out of 25 Wall Street analysts, 6 rate it as Buy, 11 as Hold, and 1 as Sell, with a median price target of $38.00.
How accurate are BAX stock price projections?
Stock price projections, including those for Baxter International Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.